HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

MRI-Guided Neoadjuvant Chemotherapy Could be Used in HR-/HER2+ Breast Cancer

April 28th 2024

MRI-guided treatment could be used to optimize the duration of neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive breast cancer.

Dr Nye on Future Treatment Directions in HER2+ Breast Cancer Brain Metastases

April 26th 2024

Lauren E. Nye, MD, discusses future directions for the treatment of patients with HER2-positive breast cancer with brain metastases.

Dr Hafez on the Design of the FeDeriCa Trial in HER2+ Early Breast Cancer

April 25th 2024

Maria Hafez, MD, discusses the design of, and outcomes from, the phase 3 FeDeriCa trial in patients with HER2-positive early breast cancer.

Dr. Tiwari on Ongoing Research in HER2+/HER2-Low Breast Cancer

April 24th 2024

Shruti Tiwari, MD, discusses efforts to address unmet needs through ongoing research in HER2-positive and HER2-low breast cancer.

Dr Tiwari on Optimal Treatment Sequencing in HER2+ Breast Cancer

April 19th 2024

Shruti Tiwari, MD, discusses treatment sequencing in HER2+ breast cancer, highlighting how to treat these patients when they present with CNS involvement.

Dr Foldi on the Evolving Role of T-DXd in HER2+ Breast Cancer

April 17th 2024

Julia Foldi, MD, PhD, discusses the evolving role of treatment with T-DXd in metastatic HER2-positive breast cancer.

Durvalumab Plus Trastuzumab/Pertuzumab Elicits Responses in HER2-Enriched Breast Cancer

April 16th 2024

Dual HER2-targeted therapy plus checkpoint blockade may offer an effective, tolerable chemotherapy alternative in HER2-positive early breast cancer.

Breast-Conserving Therapy Bests Mastectomy After Preoperative Systemic Therapy in HER2+ Breast Cancer

April 9th 2024

Following preoperative systemic therapy, breast-conserving therapy led to superior OS vs mastectomy in HER2-positive breast cancer.

Dr Nanda on Neoadjuvant Treatment in HER2+ Breast Cancer

April 4th 2024

Rita Nanda, MD, discusses the future of neoadjuvant treatment for patients with HER2-positive breast cancer.

Tiwari Highlights Updates in HER2+ and HER2-Low Breast Cancer

April 4th 2024

Shruti Tiwari, MD, discusses treatment advances in HER2-positive and HER2-low breast cancer and looks ahead to the future of the space.

Tripathy Outlines Where the HER2+ Early-Stage Breast Cancer Landscape Stands

April 3rd 2024

Debu Tripathy, MD, discusses the current treatment paradigm of HER2-positive breast cancer and highlights unmet needs that remain.

Clinical Benefits With Neratinib in HER2+ Early Breast Cancer

March 25th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.

Ongoing Research Efforts in HER2+ Early Breast Cancer

March 25th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss ongoing research efforts in HER2-positive early breast cancer.

Dr Mahtani on the Expansion of Targeted Therapies in HER2+ Breast Cancer

March 22nd 2024

Reshma L. Mahtani, DO, discusses how the expansion of HER2-targeted agents has impacted the management of HER2-positive breast cancer.

AE Management With Neratinib in HER2+ Early Breast Cancer

March 18th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.

Unmet Needs in HER2+ Early Breast Cancer

March 18th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss unmet needs in the treatment of patients with HER2-positive early breast cancer.

Evolving and Current Standards of Care for HER2+ Early Breast Cancer

March 12th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.

Prognosis and Survival Outcomes for HER2+ Early Breast Cancer

March 12th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.

HER2-Directed Therapies Continue to Shape Improved Breast Cancer Outcomes

March 10th 2024

Debu Tripathy, MD, provides insights on the management of HER2-positive breast cancer, including the evolving role of trastuzumab in this population.

T-DXd Has Intracranial Activity in Meta-Analysis of HER2+ Breast Cancer Brain Metastases

March 8th 2024

Trastuzumab deruxtecan has significant intracranial activity in patients with HER2-positive breast cancer brain metastases, regardless of subgroup.